ABAGAT

This brand name is authorized in Malta.

Active ingredients

The drug ABAGAT contains one active pharmaceutical ingredient (API):

`1`	Dabigatran UNII `2E18WX195X` - DABIGATRAN ETEXILATE
	Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma.
	Read more about Dabigatran

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AE07	Dabigatran etexilate	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AE Direct thrombin inhibitors
Discover more medicines within B01AE07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
MT	Medicines Authority	MA255/06101, MA255/06102, MA255/06103

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.